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Abstract 
The Total Thrombus-formation Analyser System (T-TAS) is a whole blood flow chamber 
system for the measurement of in vitro thrombus formation under variable shear stress 
conditions. Our current study sought to evaluate the potential utility of the T-TAS for the 
measurement of thrombus formation within human and mouse whole blood. T-TAS microchips 
(collagen, PL chip; collagen/tissue thromboplastin, AR chip) were used to analyse platelet or 
fibrin-rich thrombus formation respectively. Blood samples from humans (healthy and patients 
with mild bleeding disorders) and wild-type (WT), mice were tested. /LJKWWUDQVPLVVLRQOXPL
DJJUHJRPHWHU lumi-LTA was performed in PRP using several concentrations of ADP, 
adrenaline, arachidonic acid, collagen, PAR-1 peptide and ristocetin. Thrombus growth (N=22) 
increased with shear within PL (4:40±1.11, 3:25±0.43 and 3:12±0.48 mins [1000, 1500 and 
2000s-1]) and AR chips (3:55±0.42 and 1:49±0.19 [240s-1 and 600s-1]). The area under the curve 
(AUC) on the PL chip was also reduced at 1000s-1 compared to 1500/2000s-1 (260±51.7, 317± 
55.4 and 301±66.2 respectively).  In contrast, no differences in the AUC between 240s-1 and 
600s-1 were observed in the AR chip (1593±122 and 1591±158). The intra-assay coefficient of 
variation (CV) (n=10) in the PL chip (1000s-1) and AR chip (240s-1) were T1014.1%, T6016.7%, 
T10-6022.8% and AUC1024.4% or T10 9.03%, T808.64%, T10-8023.8% and AUC305.1%. AR chip 
thrombus formation was inhibited by rivaroxaban (1µM), but not with ticagrelor (10µM). In 
contrast, PL chip thrombus formation was totally inhibited by ticagrelor. 77$6 VKRZV DQ
RYHUDOO DJUHHPHQW ZLWK lumi-LTA LQ  RI SDWLHQWV Q  ZLWK QRUPDO SODWHOHW FRXQWV
recruited into the genotyping and phenotyping of platelet (GAPP) study and VXVSHFWHGWRKDYH
D SODWHOHW IXQFWLRQ GHIHFW The onset (T10) of thrombus formation in WT mice (N= 4) was 
shorter when compared to humans e.g. PL chip (1000s-1) T10 were 02:02±00:23 and 03:30±0:45 
respectively). T-TAS measures in vitro thrombus formation and can be used for monitoring 
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antithrombotic therapy, investigating SDWLHQWV ZLWK VXVSHFWHG SODWHOHW IXQFWLRQ GHIHFWV DQG
PRQLWRULQJSODWHOHWIXQFWLRQZLWKLQPLFH 
Keywords 
Light transmission lumi-aggregometry, mild bleeding disorders, platelet aggregation, platelet 
function defects, total thrombus-formation system, WT mice 
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Introduction 
Haemostasis is an important process that maintains the integrity of the circulatory system and 
minimises blood loss upon vascular damage. When a blood vessel-wall is injured a number of 
concomitant events occur. Initially, circulating platelets are recruited to the site of injury, where 
they are activated to become a platelet plug. Simultaneously blood coagulation is triggered by 
tissue factor resulting in thrombin generation and fibrin formation. The formation of fibrin, 
together with the platelet plug become major components of the developing thrombus at the 
sight of injury to prevent bleeding [1].  
A number of instruments have now become available to investigate bleeding disorders by 
accessing platelet function defects. However, the most common used techniques such LTA are 
aggregation based and so do not access platelet in their physiological condition. The more 
recent developed methods such as the impact cone and plate(let) analyser (CPA), PFA-200 and 
the Total Thrombus-formation Analysis System (T-TAS) are flow based methods using whole 
blood and therefore measure platelet function under more physiological conditions. Although 
both systems measure thrombus formation under high shear, CPA monitors platelet adhesion 
to a polystyrene plate and the PFA-200 measures thrombus formation within a small aperture 
[2]. Therefore, both are sensitive to VWF levels [3]. In contrast, the T-TAS has the advantage 
of evaluating thrombus formation in more physiological and variable flow conditions with 
varying effects of VWF levels [4].  
 
The T-TAS device is provided with two types of disposable ready-to-use microchips: (1) a 
platelet (PL) chip coated with collagen for assessing platelet thrombus formation and (2) an 
atherome (AR) chip coated with collagen and tissue factor for assessing white thrombus 
formation mediated by the activation of coagulation and platelets. The device therefore offers 
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a potential advantage of simultaneous assessment of both platelet and coagulation defects [5, 
6].  
 
The T-TAS was initially designed to monitor the effectiveness of antithrombotic agents. A 
number of studies have reported its potential utility in assessment of anti-platelet drugs e.g. 
aspirin, clopidogrel, PAR-1 and PAR-4 antagonists [6-8] and anti-thrombotic agents e.g. direct 
thrombin and factor Xa inhibitors [9]. T-TAS has also demonstrated high sensitivity in 
detecting coagulation disorders such as haemophilia [10] and von Willebrand disease [11], as 
well as platelet function defects for example, storage pool disease (SPD) [12]. In assessing 
acquired haemorrhagic conditions, the T-TAS was able to predict the risk of bleeding in atrial 
fibrillation patients undergoing catheter ablation [13]. Furthermore, T-TAS has been 
demonstrated to be a useful tool in the study of thrombus formation in blood taken from animal 
models such as miniature pigs [14] and mice [10, 15]. 
Materials and Methods 
Participants 
A total of 59 individuals (37 patients and 22 controls) were evaluated and recruited into the 
GAPP study (www.birmingham.ac.uk/plateletgapp) from 9 UK Haemophilia comprehensive 
care centres. All patients or their parents gave written informed consent in accordance with the 
GAPP project ethical approval (REC reference: 06/MRE07/36).    
Reagents  
ADP, ristocetin and adrenaline were purchased from Sigma (Poole, UK). Arachidonic acid and 
U46619 were purchased from Cayman Chemical Company (Michigan, USA). The PAR-1 
peptide (SFLLRN) was purchased from Severn Biotech (Kidderminster, UK). Collagen was 
purchased from Takeda (Austria) and luciferin luciferase reagent (Chrono-lume) was 
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purchased from Chrono-log Corporation (Havertown, PA, USA). The reagents were dissolved 
in phosphate-buffered saline (PBS) at pH 7.4 and stored as frozen aliquots, thawed and diluted 
in PBS when required and kept on ice. Collagen was stored as a concentrated stock at 1 mg/ml 
as supplied by the manufacturer at 4°C and diluted with the buffer provided. AR chip, PL chip, 
CaCl2 containing 1.25 mg/mL of Corn Trypsin Inhibitor (CaCTI) and 3.2% sodium citrate were 
provided by Quadratech Diagnostics Limited (Epsom, UK). ȝJPOKLUXGLQEORRGWXEHVZHUH
purchased from Roche Diagnostics (Munich, Germany). Ticagrelor (10 mM) and Rivaroxaban 
(10 mM) stock solutions were provided by Leeds Institute of Cardiovascular and metabolic 
medicine, University of Leeds (Leeds, UK). 
Blood sampling, platelet preparation and platelet count 
Whole blood (40 ml) was obtained and anticoagulated with one tenth volume of 0.109 M/L 
buffered trisodium citrate in vacutainer plastic tubes (Becton Dickinson, Plymouth, UK). An 
additional (5 ml) blood was collected, 2 ml was anticoagulated with EDTA in vacutainer plastic 
tubes (Becton Dickinson, Plymouth, UK) and 3 ml was anticoagulated with hirudin in 
vacutainer plastic tubes (Roche Diagnostics, Munich, Germany), (final concentration, 25 
ȝJPOThe same volume of blood was collected from a healthy control at the same time in 
each Centre. Blood samples were immediately transported to the testing laboratory where they 
remained capped and stored upright at room and assayed within 4 hours (by T-TAS) and within 
6 hours (by lumi-LTA) from collection. Platelet rich plasma (PRP) was prepared by 
centrifuging the citrated blood samples at 200 g for 20 min. Platelet-poor plasma (PPP) was 
prepared by further centrifugation at 1,000 g for 10 min. Both samples were transferred into 15 
ml Falcon tubes, capped and stored upright at room temperature. Whole blood platelet 
parameters were analysed from EDTA blood samples from patients and controls using the XN-
1000 whole blood counter (Sysmex UK, Milton Keynes). An impedance analyser (Coulter Z2 
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Beckman Coulter, High Wycombe, Bucks, UK) was used to count the platelets within the PRP 
by diluting 5 µl of PRP into 10 ml of fresh Isoton II diluent (Beckman Coulter, Bucks, UK).  
Platelet aggregation in platelet-rich plasma 
Tests were carried out as described previously [16].  Aggregation studies were performed by 
using a dual Chrono-log lumiaggregometer (model ChronoLog 460 VS aggregometer, 
/DE0HGLFV8.LQȝ/PLQLFXvettes and stirred at 1200 rpm at 37°C. The 100% line was 
set using autologous PPP and the 0% baseline established with native undiluted PRP.   After 
one min platelets were stimulated with ADP (10, 30, and 100 µM), adrenaline (10, 30, and 100 
µM), arachidonic acid (0.5, 1, and 1.5 mM), U46619 (1 and 3 µM), collagen (1 and 3 µg/mL), 
collagen related peptide CRP (1, 3, and 10 µg/mL), PAR-1 peptide (10, 30 and 100 µM), and 
ristocetin (1.5 and 2 mg/mL).  Platelet aggregation was monitored by measuring the change in 
optical density over 5 min after addition of the agonists and the maximal percentage of 
aggregation was recorded. ATP secretion from platelet dense granules was assessed 
simultaneously by lumi-LTA using the luciferase reagent (Chronolume) as described 
previously [16] 
Evaluation of thrombus formation under flow conditions on human blood 
In vitro thrombus formation was analysed on the T-TAS instrument (Zacros, Fujimori Kogyo 
&R/WG7RN\R-DSDQXVLQJWZRW\SHVRIPLFURFKLSVWKH3/FKLSZLGWKȝPîGHSWK
ȝPFRQWDLQLQJFDSLOODU\FKDQQHOVFRDWHGZLWKW\SHFROODJHQDQGWKH$5FKLSZidth 300 
µm, depth 60 or 120 µm, length 15 mm) (consisting of a single capillary channel coated with 
collagen and thromboplastin). The PL chip was used to analyse platelet thrombus formation 
(PTF) under three different shear rates (1000, 1500 and 2000s-1). %ULHÀ\KLUXGLQDQWLFRDJXODWHG
whole blood (320 µL) was pipetted in the reservoir then perfused at 37°C through the PL chip 
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by a pneumatic pump.  After the perfusion of blood was initiated, platelets were then activated 
by the collagen coated on the capillary. The AR chip was used to analyse white thrombus 
formation (WTF) under two different shear rates (240s-1 and 600s-1). %ULHÀ\FLWUDWHGZKROH
blood (480 µl) was re-FDOFL¿HGE\PL[LQJ with 20 µl of 0.3 M CaCTI immediately before it was 
pipetted in the reservoir. The re-FDOFL¿HGEORRGZDV then perfused at 37°C through the AR chip 
by the pneumatic pump.  After the perfusion of blood through the capillary was initiated, 
platelets and the extrinsic coagulation pathway were simultaneously activated by collagen and 
tissue thromboplastin. To prevent the outlet port from clotting, the blood is mixed with 25 mM 
EDTA (pH 10.5). The process RI WKURPEXV IRUPDWLRQ LQ ERWKFKLSVZDV PRQLWRUHGE\ ÀRZ
pressure changes in the capillary using the pressure sensor located between the pump and the 
reservoir. As thrombus formation proceeded on the coated surface, the capillary is gradually 
RFFOXGHGLQFUHDVLQJWKHÀRZSUHVVXUH%DVHGRQWKHÀRZSUHVVXUHSDWWHUQthe following four 
parameters are used to analyse the results (i) T10 (time to reach 10 kPa) was defined as the 
onset of thrombus formation and represents the duration (min) for the flow pressure to increase 
to 10 kPa from baseline due to partial occlusion of microcapillaries. (ii) OT (occlusion time) 
was defined as the complete occlusion of the capillary, which coincides with a pressure of 60 
and 80 kPa for the PL and AR chips respectively. (iii) T10±60 for PL chip and T10±80 for AR 
chip were defined as the interval between T10 and OT, representing the rate of thrombus 
JURZWKLY$8&DUHDXQGHUFXUYHLVDQDUHDXQGHUWKHÀRZSUHVVXUHFXUYHXQGHUN3D
for 10/30 min after the start of assay for the PL and AR chips respectively. AUC is used to 
quantify a decrease in WTF when OT is not achieved during the time period of assay. 
 
 
Antithrombotic effects of ticagrelor and rivaroxaban under flow conditions 
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Ticagrelor (final concentration, 10 µM) was incubated either in hirudin or citrate 
anticoagulated blood for 10 min at room temperature. Rivaroxaban (final concentration, 1 µM) 
was incubated in citrate anticoagulated blood for 3-5 min at room temperature. After incubation 
blood were perfused through either the PL chip and/or AR chip within the T-TAS instrument 
as described above.   
Statistical analysis  
All control results were run on Graph Pad Prism version 7.0 software to demonstrate the normal 
distribution and to obtain the median and standard deviation values which were then used to 
determine the cut-off values.  Abnormal results by lumi-LTA were determined based on our 
previously published methodology that is based upon both the magnitude and time course of 
response [16, 17]. The time course, including reversibility is of particular importance. In 
contrast, abnormal thrombus formation by T-TAS was determined based on the cut off values 
of AUC10 and the T10 parameters calculated as the 5th percentile from healthy controls.  
Results 
Measurement of T-TAS in healthy subjects 
22 healthy subjects (10 males and 12 females; median age 31 ± 7 years) were investigated. 
Overall, the T-TAS shows some variation in thrombus formation among healthy subjects on 
both (PL and AR) chips (Figure 1A and 1C). Within the PL chip (Figure 1B), the onset (T10) 
value (median) and occlusion time (T60) at a shear rate of 1000 s-1 were greater than at 
1500/2000 s-1 7 DQG7 UHVSHFWLYHO\In contrast, 
the AUC10 value (median) was reduced at a shear rate of 1000 s-1 than at 1500/2000 s-1 
 DQG  UHVSHFWLYHO\ Furthermore, the thrombus growth rates (T10-60) in the PL chip 
(median) decreased as the shear rate increased (04:40, 03:25 and 03:12 respectively) (Figure 
1B). A shear dependent decrease was also observed on the occlusion times (T80) and thrombus 
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growth rates (T10-80) on the AR chip 7 DQGT10-80 DQGUHVSHFWLYHO\
(Figure 1D). However, no significant different of the AUC30 values (median) was observed 
between low and high shear values (1593 and 1591 respectively).  Surprisingly, the onset (T10) 
value (median) on AR chip was greater at high shear (09:19) than at the low shear (08:16) 
(figure 1D). 
Intra-assay coefficients of variation (CV) were calculated from 10 sequential measurements of 
a single sample obtained from one healthy subject (Table 1). Overall, the difference of CV 
between shear rates within the PL chip was more significant compared to the AR chip. On PL 
chip the CVs of T60, T10-60 and AUC10 were smaller at 2000 sí 1 than at 1000/1500 sí 1 whereas 
the CVs of T10 were almost identical at all three shear rates. In AR chip however, the CV of all 
four parameters were low at 600 sí 1 than that at 240 sí 1 (Table 1). 
Measurement of blood from healthy subjects spiked with antithrombotic drugs 
No thrombus formation was observed in the PL chip when blood was pre-treated with ticagrelor 
(10 0 (Figure 1E). In contrast, thrombus formation in the AR chip was not affected by 
addition of ticagrelor (Figure 1F). However, thrombus formation in the PL chip was observed 
with blood pre-treated with rivaroxaban (1M) but varies between subjects when perfused 
through the AR chip at lower shear rates (Figure 1G).  
Measurement of T-TAS on samples from patients recruited into the GAPP study with 
suspected platelet function defects. 
We analysed 30 patients (8 male and 22 female) with a median age 35 (range 7-73) recruited 
into the GAPP study and compared T-TAS (PL chip) results with lumi-LTA. All patients had 
normal platelet counts (261 ± 68 x109/L). Of 30 patients tested (Figure 2C), 10 (33.3%) patients 
gave abnormal responses by lumi-LTA to one or more agonists as defined using previous 
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criteria [17]. In contrast, 8 (27%) patients were detected to have abnormal thrombus formation 
by T-TAS, as defined using the cut off values obtained from healthy controls. T-TAS detected 
an abnormality in 1 patient that was normal by lumi-LTA, whereas 3 samples were normal by 
T-TAS but abnormal by lumi-LTA (Figure 2A and 2B, respectively). The overall agreement 
between the two instruments is shown in table 2. 26/30 samples gave identical results by both 
tests, with the majority (19) giving normal responses, whereas 7 samples gave abnormal results 
by both tests. In contrast, there was disagreement in 4/30 samples. In this study we used AUC10 
and the T10 parameters to identify a defect on T-TAS. 7/8 (88%) samples with an abnormality 
detected by T-TAS have low values of AUC10. One patient however, had normal AUC10 value 
(AUC10=177.8s) but a delayed T10 parameter (T10 = 5.44s).  
Analysis and identification of patients with SODWHOHWIXQFWLRQGHIHFWV 
)XQFWLRQDO GHIHFWV LGHQWLILHG E\ lumi-LTA ZHUH FODVVLILHG LQWR  PDLQ JURXSV *L GHIHFWV
VHFUHWLRQGHIHFWV&2;OLNHGHIHFWDQGPXOWLSOHGHIHFWVDFFRUGLQJWRWKHLUSDWWHUQRIUHVSRQVHV
WRVSHFLILFDJRQLVWVDVSUHYLRXVO\GHVFULEHG>@$VVKRZQLQILJXUH'77$6GHWHFWHGDOO
SDWLHQWVFODVVLILHGE\ lumi-LTAZLWK&2;OLNHGHIHFWRUVHFUHWLRQGHIHFWVDQGSDWLHQWV
UHVSHFWLYHO\,QFRQWUDVW77$6RQO\GHWHFWHGSDWLHQWVZLWK*LGHIHFWVEXWRXWRIZLWK
PXOWLSOHGHIHFWV 
Measurement of T-TAS in sample from GAPP patients with thrombocytopenia recruited 
with suspected platelet function defects  
We additionally analysed 7 patients (2 male and 5 female) found to have mild to marked 
thrombocytopenia as characterized by low whole blood platelet counts (<150 x109/L), but 
normal platelet counts in PRP when tested by lumi-LTA. The whole blood platelet counts 
(mean ± SD) were 77 ± 34 (x109/L). The waveform of each individual patient is presented in 
figure 2A. AUC10 parameters (Figure 2B) showed significant differences between healthy 
12 
 
controls (n=22) and patients (n=7). All 7 patients tested exhibited abnormal thrombus 
formation within the T-TAS (Figure 2A). Interestingly, 4/7 patients were also detected by lumi-
LTA to have platelet function defects (3 secretion and 1 Cox-like defects) in additional to their 
thrombocytopenia.  
Measurement of T-TAS in samples from WT mice  
Blood samples from WT (n=5) were tested using PL chips (1000 s-1 and 2000 s-1) and AR chips 
(240 s-1). Within the PL chip, shear enhanced thrombus formation was observed with all 
parameters; however, any differences in measurements between shear rates was only 
significant with the AUC10 parameter. For example, the values (median) at 1000 s-1 (T10 = 
02:02, T60 = 04:40 and T10-60 =02:38) were greater than at 2000 s-1 (T10 = 01:16, T60 = 03:26 
and T10-60 = 02:09). Consequently, the AUC10 at 1000 s-1 was shorter than at 2000 s-1 (405.5 
and 463.6 respectively) (Table 3). The values (median) of thrombus formation within the AR 
chip (240s-1) are shown in table 3. For example, the median values of T10, T80, T10-80 and AUC30 
were 02:52, 06:41, 03:48 and 2048.98 respectively.     
The difference in thrombus formation between WT mice (n=5) and healthy humans (n=22) was 
then compared. Overall, thrombus formation in WT mice was more rapid on both the PL and 
AR chips (Figure 3A) than in humans. With PL chip measurements, the differences between 
two models were significant with all parameters. For example, WT mice values (median) at 
1000 s-1 were T10 T60 T10-60 DQG$8& WDEOHZKHUHDVWKH
YDOXHVLQKXPDQVPHGLDQDWWKHVDPHVKHDUZHUH7 7 7= 04:40DQG
$8&    UHVXOWV QRW VKRZQ In contrast, with AR chip measurements the different 
between two models were only significant with T10, T80 and AUC30 but not with T10-80 (Figure 
3C).  
Discussion 
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The T-TAS is a flow chamber system that evaluates thrombus formation using whole blood 
samples that flow on different thrombogenic surfaces under arterial or venous shear conditions. 
This approach offers an advantage for rapidly assessing thrombus formation in more 
physiological conditions using whole blood under flow. Furthermore, this method requires 
comparatively small blood volumes  ȝO making it potentially practical for clinical 
application [4]. Importantly, T-TAS has all the five requirements of flow assays methods as 
described by Roest et al. [18]. We therefore sought to evaluate the potential utility of the T-
TAS for assessing thrombus formation in blood from healthy individuals, blood spiked with 
antithrombotic agents, blood from GAPP study patients with mild bleeding disorders and blood 
from mice. 
In healthy controls, both the start and end points of thrombus formation varied among 
individuals within both chips suggesting that measurements obtained using the T-TAS may 
reflect individual variability of thrombus formation. Within the PL chip, the rate of thrombus 
formation was shorter at higher shear rates which was reflected in all parameters measured 
(Figure 1B). This supports the evidence that high-shear rates favour the GPIb-IX-V/VWF axis 
to induce more efficient thrombus formation [19]. In contrast, the effect of  the shear rate within 
the AR chip was variable, in particular the onset (T10) (Figure 1D) where the value at the high 
shear was greater than at the low shear in contrast to previous findings [4, 6]. However, an 
increased rate of thrombus growth (T10-80) in accordance with an increase in shear rate was 
observed on AR chip similar to that on PL chip, indicating that the shear rates accelerated the 
growth rate of the thrombus. Shear rate enhancement of T-TAS parameters were also reported 
by Hosokawa et al., and Yamaguchi et al., [4, 6].  In our study, the T-TAS also exhibited high 
intra-assay coefficients of variation (CV) within both chips (Table 1).  Typical CVs obtained 
were much higher than those described by Yamaguchi et al. although their sample size (n=5) 
was smaller [4].  
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We also evaluated the utility of T-TAS in detecting the effect of antithrombotic therapy on 
haemostasis using two types of drugs. 1) The antiplatelet drug Ticagrelor (P2Y12 antagonist) 
and 2) The anticoagulant Rivaroxaban (factor Xa inhibitor). Ticagrelor (10 µM) completely 
suppressed thrombus formation ZLWKLQWKH3/FKLS. These findings agree with Hokosawa et al. 
who also previously demonstrated that thrombus formation within the PL chip was inhibited 
by P2Y12 antagonists [5, 8]. In contrast, the inhibitory effect of Ticagrelor on thrombus 
formation was not observed within the AR chip. As thrombus formation within the AR at low 
shear rate is more dependent upon fibrin formation [6, 20], it is possible that P2Y12 inhibitors 
are therefore expected to have no effect in this chip as platelets play little or no role in thrombus 
formation at low shear rates [7, 21]. Secondly, platelets within the AR chip could also be 
activated via the PAR-1 receptor by thrombin which is generated from activation of the 
coagulation pathways [21]. This was demonstrated by Hokosawa et al. by demonstrating that 
PAR-1 antagonism reduced thrombus formation within the AR chip [7]. In contrast, 
Rivaroxaban (0 incubation with whole blood within the AR chip displayed considerable 
variability on affecting thrombus formation with a delayed onset despite complete thrombus 
formation (figure 1G). Hokosawa et al. also demonstrated that Rivaroxaban (0 only 
moderately suppressed thrombus formation within the AR chip [9]. However, Sugihara et al. 
demonstrated that Rivaroxaban at the estimated clinical peak dose (800 nM) significantly 
suppressed thrombus formation [22]. Furthermore, Hosokawa et al., also used T-TAS to show that 
the anticoagulant effect of thrombus formation was intensified when anticoagulant and antiplatelet 
drugs were used in combination [9]. These findings suggest that T-TAS could be a clinically useful 
tool for monitoring the antithrombotic effect on both platelet and coagulation pathways.  
 
Furthermore, we performed a comparative evaluation of the T-TAS using the PL chip with 
GAPP patients with suspected platelet function defects and compared the results with the gold 
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standard of lumi-LTA. Comparison of the overall results in 30 patients with normal platelet 
counts (Table 2) demonstrated a good agreement between T-TAS (PL chip) and lumi-LTA 
with concordance in 87% of samples tested. As 67% of samples were defined as normal by 
lumi-LTA, T-TAS therefore gave a NPV of 86% VXJJHVWLQJWKDWWKHWHVWFRXOGEHDSRWHQWLDO
VFUHHQLQJWRROIRUWKHFKDUDFWHULVDWLRQRISODWHOHWIXQFWLRQGLVRUGHUV,QWHUHVWLQJO\77$6DOVR
GHWHFWHGDOOSDWLHQWVZLWK&2;OLNHGHIHFWVDQGVHFUHWLRQGHIHFWV)LJXUH'7KLVILQGLQJLV
FRQVLVWHQWZLWKHDUOLHU UHSRUWV VKRZLQJ WKDW77$6ZDVDEOH WRGHWHFWDOOSDWLHQWVGLDJQRVHG
ZLWK63'>@77$6DOVRVKRZHGKLJKFRQVLVWHQF\LQGHWHFWLQJDEQRUPDOLWLHVLQSDWLHQWVZLWK
PXOWLSOHGHIHFWV7KLVILQGLQJVXSSRUWVWKHHDUOLHUUHSRUWVXJJHVWLQJWKDW77$6LVUHOLDEOHLQ
GHWHFWLQJPRUHVHYHUHIRUPVRISODWHOHWGHIHFWVVXFK%HUQDUG6RXOLHUV\QGURPH>@+RZHYHU
77$6 IDLOHG WR GHWHFW WKURPEXV IRUPDWLRQ LQ DOO SDWLHQWV ZLWK WKURPERF\WRSHQLD LQFOXGLQJ
WKUHHSDWLHQWVWKDWJDYHQRUPDOUHVSRQVHVE\OXPL/7$)LJXUH$DQG%7KLVPLJKWVXJJHVW
WKDW 77$6 LV QRW UHOLDEOH IRU WHVWLQJ VDPSOHV ZLWK ORZ SODWHOHW FRXQWV DQG WKDW WKURPEXV
IRUPDWLRQ LV GHSHQGHQW RQ QRUPDO SODWHOHW QXPEHUV $Q HDUOLHU VWXG\ RQ KHDOWK\ VXEMHFWV
GHPRQVWUDWHGDJRRGFRUUHODWLRQ EHWZHHQ QRUPDO SODWHOHWFRXQWVDQG77$6SDUDPHWHUV >@
)XUWKHUVWXGLHVDUHUHTXLUHGWRLQYHVWLJDWHWKHUHODWLRQVKLSEHWZHHQSODWHOHWFRXQWVDQG77$6
SDUDPHWHUV 
There is no single parameter that has been described to be more useful in defining haemostatic 
abnormalities within the T-TAS. Almost all studies evaluating bleeding disorders in the T-TAS 
have used AUC10/30 and to a lesser extent the T10 [11-13, 23].  AUC is particularly useful in 
quantifying a decrease in thrombus formation when occlusion time is not achieved during the 
time period of assay. In our study almost all samples (7/8) with abnormalities detected by T-
TAS exhibited low values of AUC10. One patient however, gave normal values of AUC10 but 
with delayed T10 parameters. Interestingly, the patient was also found to have a defect by lumi-
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LTA. This might therefore suggest that a combination of T10 and AUC parameters are sufficient 
to identify any haemostatic abnormalities on T-TAS.   
The use of comparatively small blood volumes for T-TAS makes it practical for studying ex-
vivo thrombus formation in small animal models. This could potentially result in significant 
reduction of animal usage in research laboratories. To evaluate the utility of T-TAS for testing 
thrombus formation in mouse blood, we first analysed blood samples from WT mice. WT blood 
demonstrated more rapid total thrombus formation compared to human blood. Similar results 
were reported on studies of blood from miniature pigs [14], suggesting that these animals might 
exhibit increased thrombogenicity than humans, possibly due to higher platelet counts (Table 
4). As expected, all KO models displayed poor thrombus formation within the PL chip 
concurring with previous in vivo and in vitro findings [24]. In contrast, full thrombus formation 
was observed within the AR chip with all KO indicating that the coagulation pathways are 
normal and that platelets probably have little significant contribution to thrombus formation 
using this system, at a shear rate of 240 sí1 [23]. 
Our present study has several limitations. Firstly, the study was performed with only a small 
group of patients suspected to have platelet function disorders. Therefore, for future studies it 
would be necessary to enrol a larger number of patients with known platelet function defects 
as well as other haemostatic abnormalities such as coagulation defects (e.g haemophilia and 
VWD). Secondly, the study of antithrombotic drugs was performed using a single 
concentration of either ticagrelor or rivaroxaban and were evaluated separately. It would be of 
interest in future studies to evaluate the T-TAS with a full range of antiplatelet drugs with 
different molecular targets and at different concentrations as well as in the combination with 
anticoagulant drugs. Lastly, the mouse models were only studied within the AR chip and at 
low shear rates. It would be of interest to determine if higher shear rates would also have 
detected similar platelet defects in these mice.    
17 
 
In summary, T-TAS has demonstrated a good agreement with Lumi-LTA suggesting that the 
technique could be applied to potentially screening patients with platelet function defects. 
Moreover, the device might be a useful tool in monitoring antithrombotic therapy. Finally, we 
demonstrated that the T-TAS could provide valuable assistance in rapidly studying samples 
from animal models with the potential of reducing animal usage in research laboratories.  
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Tables  
Table 1 Intra-assay coefficients of variation (CV) in PL and AR chips measurements in a single 
sample obtained from a healthy control (n=10). 
 
 
Table 2 Analysis of the agreement between the T-TAS and lumi-LTA in patient samples 
(n=30) displaying sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV).  
 
 
Table 3 T-TAS measurements in samples from WT mice (n=5) performed on both PL and AR 
chips using different shear rates. Data presented as mean and SD. 
 
Table 4 Measurement of whole blood platelet count and MPV in samples from WT mice (n=5) 
and human (n=22). Data presented as mean and SD. 
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)LJXUHOHJHQGV 
Figure 1. Measurements of blood from healthy controls (n=22) using the PL chip and AR chip. 
For panel A and C, flow pressure curves of all individuals measured at low shear rates on PL 
chip (1000 sí 1) and AR chip (240 sí 1), respectively. For panel B and D, distribution of the T-
TAS measurements from different shear rates using PL chip and AR chip, respectively. For 
panel E and F, effects of the ticagrelor (100RQblood from healthy controls (n=4) measured 
on PL chip and AR chip, respectively. For panel G, effects of the rivaroxaban (1M)RQblood 
from healthy controls (n=5) measured on AR chip (bars represent median values). Statistical 
analysis performed by the Mann Whitney U test and the one-ZD\$129$WHVWZLWK6LGDN¶V 
adjustment for multiple comparisons (***p <0.001, **p<0.01 and *p<0.05). 
Figure 2. Measurements of thrombus formation in the PL-chip (1000 sí1) with whole blood 
samples from healthy controls (n=22), patients (n=20) no detectable platelet defects by Lumi-
LTA, patients (n=10) with platelet defects as defined by lumi-LTA and patients (n=7) with 
thrombocytopenia. Panel A, flow pressure curves display control (black), normal T-TAS 
(green), abnormal T-TAS (red) and patients with thrombocytopenia (blue). Panel B, 
distribution of the T-TAS measurements display control (black circles), normal T-TAS (green 
circles), abnormal T-TAS (red circles) and patients with thrombocytopenia (blue circles). Panel 
C, sXPPDU\RIRYHUDOOSDWLHQWVUHVXOWVQ DQDO\VHGRQ lumi-LTA and T-TAScomparing 
between normal EOXHDQGDEQRUPDOUHG. Panel D, cODVVLILFDWLRQRISODWHOHWIXQFWLRQGHIHFWV
DPRQJSDWLHQWVGHWHFWHGE\lumi-LTA EOXHDQG77$6UHGThe results were considered to 
be abnormal (by lumi-LTA) as previously established in the GAPP program using samples 
from healthy subjects (Dawood et al 2012) and (by T-TAS) when they fall below the cut-off 
values (5th percentile) calculated from healthy individuals. Statistical analysis performed by the 
Mann Whitney U test (bars represent the median values). Significance as compared to control 
in each parameter (***p<0.001 and *p<0.05). 
Figure 3. Measurements of thrombus formation within the PL-chip (1000 sí1) and AR-chip 
(240 sí1) with blood from human (black) and WT mice (red). Panel A, flow pressure curves 
observed within PL-chip (1000 sí1). Panel B, distribution of the T-TAS measurements 
obtained from PL-chip (1000 sí1). Panel C, flow pressure curves observed within AR-chip 
(240 sí1). Panel D, distribution of the T-TAS measurements obtained from AR-chip (240 sí1). 
Statistical analysis performed by the Mann Whitney U test (bars represent median values). 
Significance as compared between human and WT blood in each parameter (***p<0.001). 
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